Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Apr 2 · inside the Ichimoku cloud · RSI 18 (oversold) · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in NEXI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NEXI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NEXI.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 100.0 | 50.0 | -66.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | -13.0 | -99.9 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | −99.9% |
| 2024 | 575.7 | -55.3 | -16.3 | -40.1 | -8.9 | -9.8 | -58.3 | -60.9 | -44.4 | 48.0 | 10.8 | -71.9 | −94.8% |
| 2023 | 67.3 | 5.8 | -11.6 | -5.0 | -11.2 | -12.1 | 3.0 | -24.7 | -3.9 | -29.1 | -33.3 | -10.5 | −63.5% |
| 2022 | -31.2 | -21.8 | 69.8 | -49.9 | 8.1 | -29.4 | -28.6 | 2.6 | -53.0 | 26.2 | -36.7 | -45.1 | −94.7% |
| 2021 | -26.4 | 1.2 | -3.8 | -12.2 | -34.6 | 31.8 | 7.5 | -24.8 | -30.6 | -41.6 | −82.2% |
No analyst coverage for this instrument.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.